PCN224 Knowledge On Breast Cancer Among Women In Tolna And Baranya Counties, Hungary  by Vajda, R et al.
A470  VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 3 3 5 – A 7 6 6  
Objectives: We explored the temporal relationship between PRO changes, which 
are used to measure therapeutic impact, and subsequent clinical outcomes in 
mCRPC. MethOds: COU-AA-301 was a multinational, double-blind, randomized 
phase 3 trial of abiraterone acetate plus prednisone compared with prednisone alone 
in mCRPC patients progressing after chemotherapy, with an Eastern Cooperative 
Oncology Group performance status of ≤ 2. Using data from COU-AA-301 (N = 1195) 
over the first 181 days of treatment, we explored relationships between changes 
in clinical time-to-event outcomes and PROs measuring fatigue, pain, physical 
well-being (PWB), functional well-being (FWB), and prostate cancer–specific signs 
and symptoms. Cox regression models were developed to assess the relationship 
between each PRO (separately and for all simultaneously), and overall survival 
(OS) and radiographic progression-free survival as dependent variables, adjusting 
for important baseline clinical and PRO characteristics. Results: In each indi-
vidual model, patients with PRO improvements had a reduced risk of death and 
radiographic progression compared with patients with worsening or stable PROs 
during follow-up. Hazard ratios (95% confidence intervals) for OS in patients with 
improved fatigue intensity, pain intensity, PWB, FWB, and prostate cancer-specific 
symptoms were 0.17 (0.11-0.24), 0.27 (0.18-0.41), 0.12 (0.07-0.22), 0.21 (0.12-0.35), and 
0.19 (0.12-0.28), respectively (all p < 0.0001). A significant (p < 0.0001) reduction in 
the risk of radiographic progression was seen in patients with improvements in 
fatigue intensity [0.59 (0.48-0.72)], pain intensity [0.52 (0.41-0.65)], PWB [0.47 (0.37-
0.60)], FWB [0.55 (0.44-0.69)], and prostate cancer–specific symptoms [0.56 (0.46-
0.67)]. When all end points were included in a single multivariate model, all except 
pain intensity were significantly associated with OS, whereas pain intensity, PWB, 
and FWB improvements remained significantly associated with reduced risk of 
radiographic progression. cOnclusiOns: These results demonstrate a significant 
temporal relationship between PROs and clinical outcomes, and may complement 
clinical practice methods for monitoring patients for progression.
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Will RatiNg SCale tyPeS aNd diSeaSe CoNditioNS iNflueNCe 
CoNCoRdaNCe BetWeeN CogNitive fuNCtioN RePoRted By ChildReN 
aNd theiR PaReNtS?
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Objectives: Cognitive dysfunction is a common concern for children with brain 
tumors and those who received neuro-toxic treatment. Child- and parent-reported 
cognitive function (PCF) could be used to monitor children’s cognitive performance 
overtime given their ease of administration, low cost and relevance to patients’ daily 
lives. Understanding factors contributing to discordance between child- and parent-
reported PCF could help investigators better interpret PCF. This study aims to evaluate 
whether rating scale types (intensity versus frequency) and disease status (cancer 
versus general population) influence the agreement between child- and parent-
reported PCF. MethOds: Data from 1,409 children (mean age= 12 yrs) drawn from 
the US general population and their parents and 515 children with cancer (53% brain 
tumor; mean age= 14 yrs) were analyzed. For cancer sample, 34% received radiation 
therapy, 72% chemotherapy, 71% surgery and mean years post-treatment = 3.3. All 
completed two versions of a validated pediatric perceived cognitive function short-
form (pedsPCF-SF). Both had the same 13 item stems but with different 5-point rating 
scales: 1) “frequency” (“none of the time” -- “all of the time”) and 2) “intensity” (“not 
at all” -- “very much”). Weighted Kappa was used to evaluate agreement at individual 
item level between parent- and child-reported pedsPCF-SF. Intra-class correlation 
(ICC) was used to evaluate agreement at the scale level. Results: For cancer sample, 
weighted kappas between children and parents were 0.27-0.39 for both intensity and 
frequency. For general population, weighted kappas were 0.53-0.67 and 0.64-0.70 for 
intensity and frequency, respectively. At the scale level, higher agreement was found 
on general population sample (ICC= 0.77 and 0.81 for intensity and frequency, respec-
tively) than cancer sample (ICC= 0.46 and 0.38, respectively). cOnclusiOns: Higher 
agreement was found on general population children/parents dyads compared to 
those with cancer/brain tumors at both item and scale levels. Results from this study 
can be applied to improving assessment in future pediatric studies.
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Objectives: Patient reported outcome (PRO) tools at our institution have focused 
traditionally on in-clinic evaluation. In anticipation of real time home electronic 
reporting, we assessed whether patients were willing to complete symptom/toxicity 
PRO tools prior to their clinic visits. Such tools may be more accurate and reliable but 
depend on patient motivation. MethOds: One hundred and seventy-two cancer 
outpatients were recruited at the Princess Margaret Cancer Centre. Patients were 
surveyed on their preferences for completing a currently established institutional 
electronic symptom/toxicity PRO tool when administered outside the clinic on an 
electronic platform, such as on a tablet or smartphone. Results: The median par-
ticipant age was 56.5 years and 58% were female. 74% were Caucasian and 67% had 
some post-secondary education; 58% had local disease. Of the participants, 48% 
(83/172) indicated that they would not wish to complete the PRO tool in advance of 
attending their clinic appointments and only 15% (25/172) agreed or strongly agreed. 
Fair to moderate agreement (weighted kappa= 0.41) existed between willingness/
unwillingness to complete the PRO tool in advance and willingness/unwillingness 
to fill it out electronically. Lack of willingness was not associated with any clinico-
demographic factors. Patients generally felt that the tool was not difficult to use 
(91%) and did not take too long (81%) to complete. cOnclusiOns: Patients were 
not willing to fill out a PRO tool electronically in advance of clinic visits, even though 
BRAF/MEK inhibition. MethOds: To develop a DCE to assess preferences between 
immunotherapy options (PD-1 and/or CTLA-4 inhibition) and BRAF/MEK inhibition, a 
literature review was conducted and stakeholder interviews with melanoma patients 
and oncologists were performed to determine treatment attributes and levels. The 
final survey will consist of three parts (demographics, treatment preferences, and 
the DCE section) and will be administered to patients and their treating physicians 
at the Huntsman Cancer Institute at the University of Utah. Results: The general 
information in the survey, the defined attributes and levels for melanoma treatment, 
and DCE questionnaires will be reported. The target sample for survey administra-
tion is 200 patients and up to 60 physicians. A total of 485 patients with melanoma 
within the University of Utah Health Care system are available to survey and include 
378 patients with stage I, 81 with stage II, 6 with stage III, and 20 with stage IV mela-
noma. cOnclusiOns: DCE is a potential avenue to assess patient and physician 
preferences in innovative melanoma treatments. Understanding how patients and 
physicians can be jointly involved in understanding trade-offs in treatment decisions 
will provide valuable insight into the acceptance and optimize utilization of these 
agents for the treatment of melanoma.
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Objectives: The main objective of our study was to assess a sample of the popula-
tion’s knowledge on breast cancer and screening and also to assess women’s willing-
ness to participate in the screening. MethOds: The quantitative, cross-sectional 
questionnaire survey was performed among women in two Hungarian counties. 
130 questionnaires were distributed, of which 118 proved to be evaluable. The study 
was performed in 2014 with χ 2-test as a statistical method besides 95% probability 
(p< 0.05). We used SPSS version 20.0 program. Results: The respondent women’s 
average age was 50.87±5.7SD years. 83.9% of the respondent women went to breast 
cancer screening due to an invitation letter. The respondents named the gynecolo-
gist as the most reliable source of information. Significantly more (χ 2= 9.07, p= 0.015) 
women over 50 years of age (85.7%) stayed away from screening without their doctor’s 
proposal than those of under 50 years of age (14.3%). Significantly more women with 
primary education (χ 2= 9.41 p= 0.007) stayed away from screening due to the cost than 
those with higher education. 85% of the respondent women heard about breast self-
exam. The main source of information about it is the media among the respondent 
women. 25 of them did self-exam each month. Despite of high participation rates the 
respondent women’s knowledge was superficial. On the basis of the questions con-
cerning knowledge on breast cancer risk factors and symptom only 36% of the women 
had adequate knowledge. Women with health education (χ 2= 20.00, p= 0.001) were 
significantly better informed on the issues than their counterparts. cOnclusiOns: 
Women reported an extremely high participation rate in breast screening, however, 
the overall knowledge about breast cancer of the respondents is superficial. The high 
participation rates were due to the invitation letter and the gynecologist. In the future, 
their triggering role is needed to enhance women’s awareness.
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Objectives: Over recent years, decision makers worldwide have emphasized the 
need to engage patients in healthcare policies, such as considering patient values 
in reimbursement decision making. However, integrating the preferences of numer-
ous patients towards complex healthcare technologies is challenging. We aim to 
generate patient preferences towards adjuvant chemotherapy, by deconstructing 
such preferences into different attributes. MethOds: We apply a discrete choice 
experiment to measure the relative preferences on the treatment route, length of 
treatment, accompanying cardiac toxicity, absolute relapse risk reduction and out-
of-pocket payments. We further estimate the marginal ‘willingness-to-pay’ (WTP) 
for the favored characteristics. Staff at medical center Breast Surgery Clinics carried 
out interviews with 106 patients with Stage I or Stage II breast cancer. Each par-
ticipant was asked to complete 12 formal choice tasks, with the participants being 
invited to choose one of two treatments in each choice task, or to opt out. Results: 
Our findings reveal that daily oral intake, monthly injections and a reduction in 
relapse risk were all favored by the participants, whereas quarterly injections, 
accompanying cardiac toxicity and additional out-of-pocket payments were not. 
The marginal WTP for a 2 per cent (5 per cent) reduction in relapse risk, was 1.10 
times (3.30 times) per capita GDP in Taiwan, whilst that for avoiding cardiac toxicity 
was about 1.43 times per capita GDP. The participants also had a WTP of 0.28 times 
(1.10 times) per capita GDP for a change in their treatment regimen from monthly 
(quarterly) injections to daily oral intake. cOnclusiOns: The controversy between 
decision makers and certain groups of patients, with regard to the preference among 
the latter for longer dosing intervals, reveals an urgent requirement for increased 
education and dialogue for both of these groups of stakeholders, along with the 
involvement of patients in decision making.
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